BD Horizon™ CD69 Mouse, anti-Human, RY586, Clone: FN50, BD Horizon™

Description

• The FN50 monoclonal antibody specifically binds to human CD69
• CD69 is also known as activation-induced molecule (AIM), early activation antigen (EA-1), very early activation antigen (VEA), C-type lectin domain family 2 member C (CLEC2C), MLR-3, GP32/28 and Leu-23
• CD69 is a transmembrane type II homodimer receptor
• CD69 is comprised of disulfide-linked, differentially glycosylated core protein subunits that are approximately 28 and 34 kDa in size
• Each subunit contains a C-type lectin domain.  CD69 is expressed on activated T, B, and natural killer (NK) lymphocytes, thymocytes, neutrophils, eosinophils and platelets
• In normal peripheral blood, a small and variable percentage of lymphocytes typically express detectable membrane CD69 antigen
• Upon activation, CD69 antigen expression increases on lymphocytes
• Peak CD69 expression generally occurs within 18 hours of activation, preceding the appearance of HLA-DR, IL-2Rα (CD25) and transferrin receptor (CD71)
• CD69 is highly expressed on the bright CD3+ subset of thymocytes
• FN50 monoclonal antibody labels NK cells and most lymphocytes of the follicular mantle and perifollicular/interfollicular zone as well as germinal center T cells of lymph nodes and tonsils
• Studies indicate that CD69 serves as a signaling receptor in the activation of a variety of cell types.